title: Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity.
abstract: The metabolic syndrome, recognized by the co-occurrence of general or abdominal obesity, hypertension, dyslipidemia, insulin resistance, and dysglycemia, appears to involve disturbances in metabolism, autonomic function, and health-related behaviors. However, physiological processes linking the components of the metabolic syndrome remain obscure. The current study examined associations of central nervous system serotonergic function with each metabolic syndrome risk variable, the metabolic syndrome, and physical activity. The subjects were 270 adult volunteers who participated in a study of cardiovascular disease risk factors and neurobehavioral functioning. Central serotonergic responsivity was indexed as the prolactin (PRL) response evoked by the serotonin-releasing agent, fenfluramine. Across the sample, low PRL response was associated with greater body mass index, higher concentrations of triglycerides, glucose, and insulin, higher systolic and diastolic blood pressure, greater insulin resistance, and less physical activity (P < 0.03-0.001). There also existed an inverse linear relationship between PRL response and the number of metabolic syndrome risk factors individuals possessed (P for trend = 0.002). Finally, a 1 SD decline in PRL response was associated with an odds ratio for the metabolic syndrome of 2.05 (95% confidence interval, 1.10-3.83; P = 0.002) and 5.70 (95% confidence interval, 1.69-19.25; P = 0.005), according to the definitions of the National Cholesterol Education Program and the World Health Organization, respectively. These findings reveal a heretofore unrecognized association between reduced central serotonergic responsivity and the metabolic syndrome.
authors.affiliation: Divisions of Clinical Pharmacology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15260, USA. mfm10@pitt.edu
authors.forename: Matthew F
authors.initials: MF
authors.lastname: Muldoon
authors.forename: Rachel H
authors.initials: RH
authors.lastname: Mackey
authors.forename: Katherine V
authors.initials: KV
authors.lastname: Williams
authors.forename: Mary T
authors.initials: MT
authors.lastname: Korytkowski
authors.forename: Janine D
authors.initials: JD
authors.lastname: Flory
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Manuck
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D015992:Body Mass Index; D001921:Brain / Q000503:physiopathology*; D005260:Female; D005277:Fenfluramine; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D024821:Metabolic Syndrome / Q000503:physiopathology*; D008875:Middle Aged; D009043:Motor Activity; D016017:Odds Ratio; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D011388:Prolactin / Q000097:blood; D012307:Risk Factors; D012701:Serotonin / Q000502:physiology*; D018490:Serotonin Agents; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D007328:Insulin; D018490:Serotonin Agents; D014280:Triglycerides; D005277:Fenfluramine; D012701:Serotonin; D011388:Prolactin